These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 24965900)

  • 1. Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder.
    Fleisher C; McGough J
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1157-63. PubMed ID: 24965900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder.
    Bain EE; Apostol G; Sangal RB; Robieson WZ; McNeill DL; Abi-Saab WM; Saltarelli MD
    J Clin Psychiatry; 2012 Jun; 73(6):783-9. PubMed ID: 22795204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pozanicline for the treatment of attention-deficit/hyperactivity disorder.
    Childress A; Sallee FR
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1585-93. PubMed ID: 25196198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition.
    Wilens TE; Decker MW
    Biochem Pharmacol; 2007 Oct; 74(8):1212-23. PubMed ID: 17689498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study.
    Wilens TE; Verlinden MH; Adler LA; Wozniak PJ; West SA
    Biol Psychiatry; 2006 Jun; 59(11):1065-70. PubMed ID: 16499880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults.
    Potter AS; Dunbar G; Mazzulla E; Hosford D; Newhouse PA
    Biol Psychiatry; 2014 Feb; 75(3):207-14. PubMed ID: 23856296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder.
    Barton J
    Arch Dis Child; 2005 Feb; 90 Suppl 1(Suppl 1):i26-9. PubMed ID: 15665154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Atomoxetine safety and efficacy in children with attention deficit/hyperactivity disorder (ADHD): initial phase of 10-week treatment in a relapse prevention study with a Spanish sample].
    Escobar R; Soutullo C; San Sebastián J; Fernández E; Julián I; Lahortiga F
    Actas Esp Psiquiatr; 2005; 33(1):26-32. PubMed ID: 15704028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments.
    Prince JB
    Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):13-50. PubMed ID: 16321724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-stimulant medications in the treatment of ADHD.
    Banaschewski T; Roessner V; Dittmann RW; Santosh PJ; Rothenberger A
    Eur Child Adolesc Psychiatry; 2004; 13 Suppl 1():I102-16. PubMed ID: 15322961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
    Davids E; Gastpar M
    Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the α4β2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain.
    Rowbotham MC; Arslanian A; Nothaft W; Duan RW; Best AE; Pritchett Y; Zhou Q; Stacey BR
    Pain; 2012 Apr; 153(4):862-868. PubMed ID: 22386472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α4β2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of α4β2 nAChR agonists in pain.
    Lee CH; Zhu C; Malysz J; Campbell T; Shaughnessy T; Honore P; Polakowski J; Gopalakrishnan M
    Biochem Pharmacol; 2011 Oct; 82(8):959-66. PubMed ID: 21763685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
    Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
    Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study.
    Apostol G; Abi-Saab W; Kratochvil CJ; Adler LA; Robieson WZ; Gault LM; Pritchett YL; Feifel D; Collins MA; Saltarelli MD
    Psychopharmacology (Berl); 2012 Feb; 219(3):715-25. PubMed ID: 21748252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled crossover study of α4β 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder.
    Jucaite A; Öhd J; Potter AS; Jaeger J; Karlsson P; Hannesdottir K; Boström E; Newhouse PA; Paulsson B
    Psychopharmacology (Berl); 2014 Mar; 231(6):1251-65. PubMed ID: 23640072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.